A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may have disease modifying effects when used early in the course of disease.

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

ORLANDO -- Adding four monthly infusions of novel ianalumab helped adults with primary immune thrombocytopenia (ITP) achieve ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia (ITP) by 45%, according to data ...

EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...

Tune in to a powerful episode of the AscellaHealth Podcast Pulse, released in recognition of Rare Disease Awareness Month. Hosted by Gabriella Patone of AscellaHealth, this special edition features an ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with ...